Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Goodwill (2022 - 2024)

Neurocrine Biosciences filings provide 3 years of Goodwill readings, the most recent being $5.7 million for Q4 2024.

  • On a quarterly basis, Goodwill fell 1.72% to $5.7 million in Q4 2024 year-over-year; TTM through Dec 2024 was $5.7 million, a 1.72% decrease, with the full-year FY2024 number at $5.7 million, down 1.72% from a year prior.
  • Goodwill hit $5.7 million in Q4 2024 for Neurocrine Biosciences, down from $6.1 million in the prior quarter.
  • In the past five years, Goodwill ranged from a high of $6.1 million in Q3 2024 to a low of $5.4 million in Q4 2022.
  • Median Goodwill over the past 3 years was $5.7 million (2023), compared with a mean of $5.7 million.
  • The widest YoY moves for Goodwill: up 10.91% in 2024, down 1.72% in 2024.
  • Neurocrine Biosciences' Goodwill stood at $5.4 million in 2022, then increased by 7.41% to $5.8 million in 2023, then dropped by 1.72% to $5.7 million in 2024.
  • The last three reported values for Goodwill were $5.7 million (Q4 2024), $6.1 million (Q3 2024), and $5.7 million (Q2 2024) per Business Quant data.